医薬品受託製造市場規模、成長と動向分析レポート 2026-2033年

世界の医薬品受託製造市場規模は、2025年に1,417億4,000万米ドルと推定され、2033年には3,109億7,000万米ドルに成長し、2026年から2033年にかけての年平均成長率（CAGR）は10.45%に達するとGrand View Researchでは予測しています。医薬品メーカーにおける臨床試験および商業生産ワークフローの再構築の急増に伴い、受託製造の需要が高まっています。

主要市場動向と洞察

• 北米の医薬品受託製造業界は、2025年に世界市場の38.44%を占め、最大のシェアを獲得しました。
• 米国の医薬品受託製造市場は、予測期間中に大幅な成長が見込まれています。
• サービス別に見ると、原薬（API）製造セグメントが2025年に70.68%の最大の市場シェアを占めました。
• 製品別に見ると、低分子医薬品セグメントが2025年に最大の市場シェアを占めました。

製薬業界では、複雑な製造工程を受託製造機関（CMO）などの専門パートナーに委託する動きが強まっており、これが市場の成長を後押ししています。

さらに、多くの中小規模の製薬会社はCMOの恩恵を受けており、CMOは自社のコアコンピタンスに集中し、製造工程の複雑な部分を委託先企業に任せることを可能にしています。加えて、多くの受託製造業者は、生産量の増加を支える様々な無菌充填装置の提供に特化しており、品質を損なうことなく医薬品製造プロセスをさらに強化しています。さらに、創薬技術の飛躍的な進歩と、製品が業界標準を満たすことを保証するための品質管理システムへの注目の高まりも、市場の成長を牽引しています。

急速な技術進歩は、効率性を向上させながら効果的な医薬品カスタマイズを可能にするために、受託製造のあり方をも変えつつあります。高度な製造技術、データ分析、人工知能（AI）、品質設計（QbD）、プロセス分析技術（PAT）などの技術進歩は、医薬品開発期間を短縮するための新たな製造能力に対する継続的な進化と需要を支えています。例えば、データ分析とAIは、製造プロセス全体で生成される膨大な量のデータを活用することで、製薬業界のさまざまな側面を変革しており、生産の最適化、機器の故障予測、規制遵守の確保をさらに支援することができます。さらに、製剤開発と臨床試験製造の専門知識を持つCMOは、AI主導の発見を実際の治療へと加速させることが期待されています。また、ブランド医薬品とジェネリック医薬品に対する需要の高まりは、市場成長の重要な要因の一つです。

本レポートは、世界、地域、国レベルでの収益成長を予測し、2021年から2033年までの各サブセグメントにおける最新の業界動向を分析しています。本調査において、Grand View Researchは、世界の医薬品受託製造市場レポートを、サービス、製品、事業規模、ワークフロー、アプリケーション、最終用途、企業規模、地域に基づいてセグメント化しました。

Pharmaceutical Contract Manufacturing Market Summary

The pharmaceutical industry is witnessing a shift toward assigning complex manufacturing processes to specialized partners like contract manufacturing organizations (CMOs), reinforcing the growth of the market.

Furthermore, most small-to-mid-sized pharmaceutical companies benefit from CMOs, which support them focus on their core competencies and tackle the complexities of production for a company contracting them. In addition, most contract manufacturing providers specialize in the availability of various sterile filling equipment that supports increased production, further enhancing the process of drug production without compromising quality. Besides, the surge in drug discovery techniques and growing focus on quality control systems to ensure that products meet industry standards drive the market growth.

Moreover, rapid technological advances are also reshaping contract manufacturing to improve efficiency while enabling effective drug customization. Technological advancements such as advanced manufacturing technologies, data analytics and artificial intelligence (AI) and quality by design (QbD) and process analytical technology (PAT) support continuous evolution and demand for new manufacturing capacities to accelerate drug development timelines. For instance, data analytics and AI are transforming various aspects of the pharmaceutical industry by harnessing major amounts of data generated throughout the manufacturing process, it can further support optimizing production, predict equipment failures, and ensure regulatory compliance. Moreover, CMOs with expertise in formulation development and clinical trial production are expected to boost the AI-driven discoveries into real-world treatments. Moreover, growing requirement for branded and generic drugs is one of the significant factors for the growth of the market.

Thus, the role of contract manufacturing (CMOs) in the pharmaceutical industry offers a comprehensive range of tailored solutions from pharmaceutical development to commercial services, further accelerating drug development, minimizing the cost, and improving efficiency.

Market Concentration & Characteristics

The pharmaceutical contract manufacturing industry growth stage is medium, and growth is accelerating. The market is characterized by the level of merger & acquisitions activities, degree of innovation, regulatory impact, product expansion, and regional expansions.

Pharmaceutical contract manufacturing is adopting innovation through continuous manufacturing, AI-driven process optimization, single-use technologies, and advanced biologics production. These advancements improve efficiency, enhance quality control, and allow for better scalability, positioning CMOs as essential partners in the evolving global pharmaceutical landscape.

Stringent global regulatory standards and the need to comply with agencies FDA, EMA, and ICH regulations drive quality, compliance, and transparency in pharmaceutical contract manufacturing. GMP requirements, data integrity standards, and evolving regulatory frameworks impact CMOs operations, ensuring safe, high-quality drug production while increasing costs, complexity, and supply chain scrutiny.

Mergers and acquisitions (M&A) in pharmaceutical contract manufacturing are surging, driven by technological advancements, and expanding service portfolios. In addition, the CMOs are acquiring specialized firms to enhance biologics, HPAPI, and sterile manufacturing capabilities, strengthening global supply chains and competitiveness.

The market for pharmaceutical contract manufacturing remains fragmented, with numerous CMOs catering to small molecules, biologics, and specialty drugs. Besides, cost advantages, and regulatory compliance have led the market competitive fragmentation.

Pharmaceutical contract manufacturing is witnessing rapid regional expansion, with CMOs investing in developed and developing economics to leverage cost efficiencies and favorable regulations, which further fuel market growth.

Service Insights

Based on service segment, the market is segmented into API Manufacturing, finished drug product manufacturing, and packaging services. Finished drug product manufacturing further includes oral solids, liquids, topical, and others. The API manufacturing segment captured the largest market share of 70.68% in 2025. This significant growth can be attributed to rising outsourcing trends, cost efficiency, and the need for regulatory compliance. Producing active pharmaceutical ingredients (APIs) is one of the most critical processes in pharmaceutical production, as it helps create lifesaving medications for patients.

The packaging services segment is expected to grow at the fastest CAGR over the forecast period. The growth is due to increasing demand for lifesaving pharmaceuticals and the rising partnerships among pharmaceutical companies and contract manufacturing organizations (CMOs) to provide a range of services, including manufacturing and packaging. In addition, the need for cost-effective packaging solutions and the requirement for packaging of lifesaving medications are crucial in ensuring that these products reach patients effectively.

Innovations in the primary packaging industry are also becoming more prevalent, particularly for small-batch production. Furthermore, pharmaceutical contract manufacturing has emerged significantly, leading to increased production capacity and reduced time-to-market for new product launches. This segment offers various packaging options, including blister packaging, bottle and vial packaging, ampoule and capsule packaging, tubes, sachets, pouches, and stick packs. These solutions help pharmaceutical companies enhance efficiency and maintain product integrity throughout the supply chain, from primary packaging and labeling to shipping, storage, and distribution to end users. This trend is expected to drive market growth over the estimated time.

Product Insights

Based on product segment, the market is segmented into small molecules and biologics. Biologics further includes monoclonal antibodies, vaccines, recombinant proteins, and others. The small molecules segment dominated the global market in 2025. Small-molecule drugs have been the backbone of the pharmaceutical industry for nearly a century. The segment growth is driven by the increasing volume of small molecule production; growing advantages CMOs offer will simplify manufacturing compared to large molecule biologics.

The biologics segment is expected to grow at significant CAGR over the forecast period. This growth is attributed to high investments and ongoing innovation in therapeutic & other medications. In addition, the increasing adoption of advanced technologies such as artificial intelligence, the rising outsourcing trends, and the growing research and development (R&D) activities by pharmaceutical companies are key factors propelling the segment’s growth.

Drug Insights

On the basis of drug segment, the market is segmented into generics and branded.  The generics segment accounted for the largest market share in 2025. The segment growth is driven by rising patent expirations, increased outsourcing by pharmaceutical companies, and rising requirements for cost-effective medicines. Besides, continuous manufacturing trends and technological advancement have led the segment to grow. Furthermore, the low manufacturing costs have encouraged various pharmaceutical companies in developed economies to outsource their manufacturing activities to CMOs.

The branded segment is expected to grow at a considerable CAGR during the forecast period. The branded drug contract manufacturing market is experiencing steady growth as pharmaceutical companies increasingly outsource production to Contract Manufacturing Organizations (CMOs). Moreover, due to the rising complexity of drug formulations, most pharmaceutical manufacturers producing branded drugs are turning to contract manufacturing organizations for their expertise in advanced formulations, biologics, sterile injectables, and novel drug delivery systems.

Scale of Operation Insights

On the basis of the scale of the operation segment, the market is segmented into batch and continuous segments. The batch segment dominated the market in 2025. A key trend in the market is batch outsourcing, as it offers smaller companies the opportunity to save operational costs and significantly reduces the preparation and adjustment of equipment before commencing the production of each batch. Such factors are anticipated to drive the segment growth.

The continuous segment is expected to experience significant growth at a specific (CAGR) during the forecast period. Pharmaceutical continuous manufacturing (CM) is considered a crucial technology in the pharmaceutical contract manufacturing process, with a growing emphasis on producing innovative drugs. The segment growth can be attributed to greater efficiency, cost reduction, and improved product quality.

Workflow Insights

On the basis of the workflow segment, the market is segmented into clinical and commercial. The commercial segment dominated the global market in 2025 owing to a strong pipeline for pharmaceutical drug development, and large-scale commercial manufacturing, among others. In addition, several pharmaceutical companies are turning to commercial contract manufacturing to access advanced infrastructure and expertise due to the increasing influx of novel therapies & orphan drugs and higher returns on approved products.

The clinical segment is anticipated registering a significant CAGR during the forecast period. The segment is driven by growing number of clinical trials and increasing demand for specialized CMO services. Such factors are anticipated to drive the market.

Application Insights

On the basis of the application segment, the market is segmented into oncology, infectious diseases, neurological disorders, cardiovascular diseases, metabolic disorders, autoimmune diseases, respiratory diseases, ophthalmology, gastrointestinal disorders, hormonal disorders, hematological disorders, and others.

The oncology segment dominated the global market and accounted for a largest revenue share in 2025. The segment is expected to grow due to the increasing number of cancer cases worldwide. For instance, the Cancer Atlas mentioned that there will be 29 million cancer cases across the globe by 2040. Recent trends in pharmaceutical products have shifted with growing R&D for cancer treatments.

The cardiovascular diseases segment is expected to experience significant growth at a specific (CAGR) during the forecast period. The segment is driven by the increasing prevalence of cardiovascular diseases, which has fueled the segment’s growth. For instance, according to World Heart Report 2023, it revealed that over half a billion people globally are affected with cardiovascular diseases, resulting in nearly a million deaths. Hence, the growing innovation of pharmaceutical products is expected to propel market growth.

End Use Insights

On the basis of the end use segment, the market is segmented into pharmaceutical and biotechnology companies. The pharmaceutical companies segment dominated the market in 2025 owing to the increasing trend of outsourcing end-to-end services, especially among small and mid-sized pharmaceutical companies that lack expertise in drug development.

The biotechnology companies’ segment is expected to experience significant growth at a specific (CAGR) rate during the forecast period. Increasing preference for outsourcing among biotechnology, midsized biotechnology, and emerging companies to gain better knowledge of outsourcing pharmaceutical drugs has led the growth of market. Likewise, an increasing number of new pharmaceutical drugs contribute to market growth.

Company Size Insights

On the basis of the company size segment, the market is segmented into small, medium, and large. The small company size segment dominated the market with the largest revenue share in 2025. The high growth of the segment is mainly due to the presence of growing employee strengths, facilities and increasing venture funding.

The medium segment is expected to grow at a significant CAGR during the forecast period. Most medium or “midsized” companies have 100 to 500 employees participating in the end-to-end development of innovative drugs; however, their concentration is limited to specific therapy areas.

Key Pharmaceutical Contract Manufacturing Company Insights

Market players are undertaking various strategic initiatives, such as the launch of new product innovations, collaborations, partnerships, and mergers & acquisitions, to strengthen their service offering and provide a competitive advantage. For instance, in March 2024, Tonix Pharmaceuticals Holding Corp. mentioned that it has selected two CMOs including Almac Pharma Services, to potentially produce Tonmya for commercial use in the U.S. The company is excited to move its first internally developed program toward NDA submission & to collaborate with CMOs for commercial supply and potential launch of Tonmya.

Recent Developments

• In October 2024, Samsung Biologics mentioned a contract manufacturing partnership with an Asian pharmaceutical company. This partnership is valued at USD 1.24 billion, making it one of the most significant contracts signed by a single client to date. In addition, the production will take place in South Korea at Samsung Biologics’ biomanufacturing facility, and the partnership will run through December 2037. With the agreement, Samsung Biologics’ total contracts for 2024 have exceeded USD 3.3 billion.

• In March 2023, Pfizer mentioned a USD 183 million contract manufacturing partnership with Samsung Biologics. In addition, after two years, the Samsung Biologics mentioned the agreement to manufacture COVID-19 vaccines for Moderna, as well as for other leading mRNA vaccine producers, including Pfizer. This is the first time Korea’s top conglomerate Samsung Group’s biotechnology unit unveiled its CMO contract with Pfizer.

Global Pharmaceutical Contract Manufacturing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pharmaceutical contract manufacturing market report based on service, product, scale of operation, workflow, application, end use, company size, and region:

• Service Outlook (Revenue, USD Million, 2021 – 2033)
  • API Manufacturing
  • Finished Drug Product Manufacturing
    • Oral Solids
    • Liquids
    • Topical
    • Others
  • Packaging Services
• Product Outlook (Revenue, USD Million, 2021 – 2033)
  • Small Molecule
  • Biologics
    • Monoclonal Antibodies
    • Vaccines
    • Recombinant Proteins
    • Others
• Drug Outlook (Revenue, USD Million, 2021 – 2033)
  • Generics
  • Branded
• Scale of Operation Outlook (Revenue, USD Million, 2021 – 2033)
  • Batch
  • Continuous
• Workflow Outlook (Revenue, USD Million, 2021 – 2033)
  • Clinical
  • Commercial
• Application Outlook (Revenue, USD Million, 2021 – 2033)
  • Oncology
  • Infectious Diseases
  • Neurological Disorders
  • Cardiovascular Disease
  • Metabolic Disorders
  • Autoimmune Diseases
  • Respiratory Diseases
  • Ophthalmology
  • Gastrointestinal Disorders
  • Hormonal Disorders
  • Hematological Disorders
  • Others
• End Use Outlook (Revenue, USD Million, 2021 – 2033)
  • Pharmaceutical Companies
  • Biotechnology companies
• Company Size Outlook (Revenue, USD Million, 2021 – 2033)
  • Small
  • Medium
  • Large
• Regional Outlook (Revenue, USD Million, 2021 – 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Thailand
    • South Korea
    • Australia
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
    • Oman
    • Qatar

Table of Contents

Chapter 1. Research Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Service
1.2.2. Product
1.2.3. Drug
1.2.4. Scale of Operation
1.2.5. Workflow
1.2.6. Application
1.2.7. End Use
1.2.8. Company Size
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.7.2. Parent Market Analysis
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Pharmaceutical Contract Manufacturing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Technological Advancements
3.4. Clinical trials volume analysis (2024)
3.5. Pharmaceutical Contract Manufacturing Market Analysis Tools
3.5.1. Industry Analysis – Porter’s Five Analysis
3.5.2. PESTEL Analysis
3.5.3. COVID-19 Impact Analysis
Chapter 4. Pharmaceutical Contract Manufacturing Market: Service Estimates & Trend Analysis
4.1. Pharmaceutical Contract Manufacturing Market, By Service: Segment Dashboard
4.2. Pharmaceutical Contract Manufacturing Market, By Service: Movement Analysis
4.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Service, 2021 – 2033
4.4. API Manufacturing
4.4.1. API Manufacturing Market Revenue Estimates and Forecasts, 2021 – 2033 (USD Million)
4.5. Finished Drug Product Manufacturing
4.5.1. Finished Drug Product Manufacturing Market Revenue Estimates and Forecasts, 2021 – 2033 (USD Million)
4.5.2. Oral Solids
4.5.2.1. Oral Solids Market Revenue Estimates and Forecasts, 2021 – 2033 (USD Million)
4.5.3. Liquids
4.5.3.1. Liquids Market Revenue Estimates and Forecasts, 2021 – 2033 (USD Million)
4.5.4. Topical
4.5.4.1. Topical Market Revenue Estimates and Forecasts, 2021 – 2033 (USD Million)
4.5.5. Others
4.5.5.1. Others Market Revenue Estimates and Forecasts, 2021 – 2033 (USD Million)
4.6. Packaging Services
4.6.1. Packaging Services Market Revenue Estimates and Forecasts, 2021 – 2033 (USD Million)
Chapter 5. Pharmaceutical Contract Manufacturing Market: Product Estimates & Trend Analysis
5.1. Pharmaceutical Contract Manufacturing Market, By Product: Segment Dashboard
5.2. Pharmaceutical Contract Manufacturing Market, By Product: Movement Analysis
5.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Product, 2021 – 2033
5.4. Small Molecule
5.4.1. Small Molecule Market Revenue Estimates and Forecasts, 2021 – 2033 (USD Million)
5.5. Biologics
5.5.1. Biologics Market Revenue Estimates and Forecasts, 2021 – 2033 (USD Million)
5.5.2. Monoclonal Antibodies
5.5.2.1. Monoclonal Antibodies Market Revenue Estimates and Forecasts, 2021 – 2033 (USD Million)
5.5.3. Vaccines
5.5.3.1. Vaccines Market Revenue Estimates and Forecasts, 2021 – 2033 (USD Million)
5.5.4. Recombinant Proteins
5.5.4.1. Recombinant Proteins Market Revenue Estimates and Forecasts, 2021 – 2033 (USD Million)
5.5.5. Others
5.5.5.1. Others Market Revenue Estimates and Forecasts, 2021 – 2033 (USD Million)
Chapter 6. Pharmaceutical Contract Manufacturing Market: Drug Estimates & Trend Analysis
6.1. Pharmaceutical Contract Manufacturing Market, By Drug: Segment Dashboard
6.2. Pharmaceutical Contract Manufacturing Market, By Drug: Movement Analysis
6.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Drug, 2021 – 2033
6.4. Generics
6.4.1. Generics Market Revenue Estimates and Forecasts, 2021 – 2033 (USD Million)
6.5. Branded
6.5.1. Branded Market Revenue Estimates and Forecasts, 2021 – 2033 (USD Million)
Chapter 7. Pharmaceutical Contract Manufacturing Market: Scale of Operation Estimates & Trend Analysis
7.1. Pharmaceutical Contract Manufacturing Market, By Scale of Operation: Segment Dashboard
7.2. Pharmaceutical Contract Manufacturing Market, By Scale of Operation: Movement Analysis
7.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Scale of Operation, 2021 – 2033
7.4. Batch
7.4.1. Batch Market Revenue Estimates and Forecasts, 2021 – 2033 (USD Million)
7.5. Continuous
7.5.1. Continuous Market Revenue Estimates and Forecasts, 2021 – 2033 (USD Million)
Chapter 8. Pharmaceutical Contract Manufacturing Market: Workflow Estimates & Trend Analysis
8.1. Pharmaceutical Contract Manufacturing Market, By Workflow: Segment Dashboard
8.2. Pharmaceutical Contract Manufacturing Market, By Workflow: Movement Analysis
8.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Workflow, 2021 – 2033
8.4. Clinical
8.4.1. Clinical Market, 2021 to 2033 (USD Million)
8.5. Commercial
8.5.1. Commercial Market, 2021 to 2033 (USD Million)
Chapter 9. Pharmaceutical Contract Manufacturing Market: Application Estimates & Trend Analysis
9.1. Pharmaceutical Contract Manufacturing Market, By Application: Segment Dashboard
9.2. Pharmaceutical Contract Manufacturing Market, By Application: Movement Analysis
9.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Application, 2021 – 2033
9.4. Oncology
9.4.1. Oncology Market, 2021 to 2033 (USD Million)
9.5. Infectious Diseases
9.5.1. Infectious Diseases Market, 2021 to 2033 (USD Million)
9.6. Neurological Disorders
9.6.1. Neurological Disorders Market, 2021 to 2033 (USD Million)
9.7. Cardiovascular Disease
9.7.1. Cardiovascular Disease Market, 2021 to 2033 (USD Million)
9.8. Metabolic Disorders
9.8.1. Metabolic Disorders Market, 2021 to 2033 (USD Million)
9.9. Autoimmune Diseases
9.9.1. Autoimmune Diseases Market, 2021 to 2033 (USD Million)
9.10. Respiratory Diseases
9.10.1. Respiratory Diseases Market, 2021 to 2033 (USD Million)
9.11. Ophthalmology
9.11.1. Ophthalmology Market, 2021 to 2033 (USD Million)
9.12. Gastrointestinal Disorders
9.12.1. Gastrointestinal Disorders Market, 2021 to 2033 (USD Million)
9.13. Hormonal Disorders
9.13.1. Hormonal Disorders Market, 2021 to 2033 (USD Million)
9.14. Hematological Disorders
9.14.1. Hematological Disorders Market, 2021 to 2033 (USD Million)
9.15. Others
9.15.1. Others Market, 2021 to 2033 (USD Million)
Chapter 10. Pharmaceutical Contract Manufacturing Market: End Use Estimates & Trend Analysis
10.1. Pharmaceutical Contract Manufacturing Market, By End Use: Segment Dashboard
10.2. Pharmaceutical Contract Manufacturing Market, By End Use: Movement Analysis
10.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By End Use, 2021 – 2033
10.4. Pharmaceutical Companies
10.4.1. Pharmaceutical Companies Market, 2021 to 2033 (USD Million)
10.5. Biotechnology Companies
10.5.1. Biotechnology Companies Market, 2021 to 2033 (USD Million)
Chapter 11. Pharmaceutical Contract Manufacturing Market: Company Size Estimates & Trend Analysis
11.1. Pharmaceutical Contract Manufacturing Market, By Company Size: Segment Dashboard
11.2. Pharmaceutical Contract Manufacturing Market, By Company Size: Movement Analysis
11.3. Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Company Size, 2021 – 2033
11.4. Small
11.4.1. Small Market, 2021 to 2033 (USD Million)
11.5. Medium
11.5.1. Medium Market, 2021 to 2033 (USD Million)
11.6. Large
11.6.1. Large Market, 2021 to 2033 (USD Million)
Chapter 12. Pharmaceutical Contract Manufacturing Market: Regional Estimates & Trend Analysis
12.1. Regional Market Share Analysis, 2024 & 2030
12.2. Regional Market Dashboard
12.3. Global Regional Market Snapshot
12.4. North America
12.4.1. North America Market Estimates and Forecasts, 2021 – 2033 (USD Million)
12.4.2. U.S
12.4.2.1. Key Country Dynamics
12.4.2.2. Competitive Scenario
12.4.2.3. Regulatory Framework
12.4.2.4. U.S. Market Estimates and Forecasts, 2021 – 2033 (USD Million)
12.4.3. Canada
12.4.3.1. Key Country Dynamics
12.4.3.2. Competitive Scenario
12.4.3.3. Regulatory Framework
12.4.3.4. Canada Market Estimates and Forecasts, 2021 – 2033 (USD Million)
12.4.4. Mexico
12.4.4.1. Key Country Dynamics
12.4.4.2. Competitive Scenario
12.4.4.3. Regulatory Framework
12.4.4.4. Mexico Market Estimates and Forecasts, 2021 – 2033 (USD Million)
12.5. Europe
12.5.1. Europe Market Estimates and Forecasts, 2021 – 2033 (USD Million)
12.5.2. UK
12.5.2.1. Key Country Dynamics
12.5.2.2. Competitive Scenario
12.5.2.3. Regulatory Framework
12.5.2.4. UK Market Estimates and Forecasts, 2021 – 2033 (USD Million)
12.5.3. Germany
12.5.3.1. Key Country Dynamics
12.5.3.2. Competitive Scenario
12.5.3.3. Regulatory Framework
12.5.3.4. Germany Market Estimates and Forecasts, 2021 – 2033 (USD Million)
12.5.4. France
12.5.4.1. Key Country Dynamics
12.5.4.2. Competitive Scenario
12.5.4.3. Regulatory Framework
12.5.4.4. France Market Estimates and Forecasts, 2021 – 2033 (USD Million)
12.5.5. Italy
12.5.5.1. Key Country Dynamics
12.5.5.2. Competitive Scenario
12.5.5.3. Regulatory Framework
12.5.5.4. Italy Market Estimates and Forecasts, 2021 – 2033 (USD Million)
12.5.6. Spain
12.5.6.1. Key Country Dynamics
12.5.6.2. Competitive Scenario
12.5.6.3. Regulatory Framework
12.5.6.4. Spain Market Estimates and Forecasts, 2021 – 2033 (USD Million)
12.5.7. Denmark
12.5.7.1. Key Country Dynamics
12.5.7.2. Competitive Scenario
12.5.7.3. Regulatory Framework
12.5.7.4. Denmark Market Estimates and Forecasts, 2021 – 2033 (USD Million)
12.5.8. Sweden
12.5.8.1. Key Country Dynamics
12.5.8.2. Competitive Scenario
12.5.8.3. Regulatory Framework
12.5.8.4. Sweden Market Estimates and Forecasts, 2021 – 2033 (USD Million)
12.5.9. Norway
12.5.9.1. Key Country Dynamics
12.5.9.2. Competitive Scenario
12.5.9.3. Regulatory Framework
12.5.9.4. Norway Market Estimates and Forecasts, 2021 – 2033 (USD Million)
12.6. Asia Pacific
12.6.1. Asia Pacific Market Estimates and Forecasts, 2021 – 2033 (USD Million)
12.6.2. Japan
12.6.2.1. Key Country Dynamics
12.6.2.2. Competitive Scenario
12.6.2.3. Regulatory Framework
12.6.2.4. Japan Market Estimates and Forecasts, 2021 – 2033 (USD Million)
12.6.3. China
12.6.3.1. Key Country Dynamics
12.6.3.2. Competitive Scenario
12.6.3.3. Regulatory Framework
12.6.3.4. China Market Estimates and Forecasts, 2021 – 2033 (USD Million)
12.6.4. India
12.6.4.1. Key Country Dynamics
12.6.4.2. Competitive Scenario
12.6.4.3. Regulatory Framework
12.6.4.4. India Market Estimates and Forecasts, 2021 – 2033 (USD Million)
12.6.5. Thailand
12.6.5.1. Key Country Dynamics
12.6.5.2. Competitive Scenario
12.6.5.3. Regulatory Framework
12.6.5.4. Thailand Market Estimates and Forecasts, 2021 – 2033 (USD Million)
12.6.6. South Korea
12.6.6.1. Key Country Dynamics
12.6.6.2. Competitive Scenario
12.6.6.3. Regulatory Framework
12.6.6.4. South Korea Market Estimates and Forecasts, 2021 – 2033 (USD Million)
12.6.7. Australia
12.6.7.1. Key Country Dynamics
12.6.7.2. Competitive Scenario
12.6.7.3. Regulatory Framework
12.6.7.4. Australia Market Estimates and Forecasts, 2021 – 2033 (USD Million)
12.7. Latin America
12.7.1. Latin America Market Estimates and Forecasts, 2021 – 2033 (USD Million)
12.7.2. Brazil
12.7.2.1. Key Country Dynamics
12.7.2.2. Competitive Scenario
12.7.2.3. Regulatory Framework
12.7.2.4. Brazil Market Estimates and Forecasts, 2021 – 2033 (USD Million)
12.7.3. Argentina
12.7.3.1. Key Country Dynamics
12.7.3.2. Competitive Scenario
12.7.3.3. Regulatory Framework
12.7.3.4. Argentina Market Estimates and Forecasts, 2021 – 2033 (USD Million)
12.8. MEA
12.8.1. MEA Market Estimates and Forecasts, 2021 – 2033 (USD Million)
12.8.2. South Africa
12.8.2.1. Key Country Dynamics
12.8.2.2. Competitive Scenario
12.8.2.3. Regulatory Framework
12.8.2.4. South Africa Market Estimates and Forecasts, 2021 – 2033 (USD Million)
12.8.3. Saudi Arabia
12.8.3.1. Key Country Dynamics
12.8.3.2. Competitive Scenario
12.8.3.3. Regulatory Framework
12.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 – 2033 (USD Million)
12.8.4. UAE
12.8.4.1. Key Country Dynamics
12.8.4.2. Competitive Scenario
12.8.4.3. Regulatory Framework
12.8.4.4. UAE Market Estimates and Forecasts, 2021 – 2033 (USD Million)
12.8.5. Kuwait
12.8.5.1. Key Country Dynamics
12.8.5.2. Competitive Scenario
12.8.5.3. Regulatory Framework
12.8.5.4. Kuwait Market Estimates and Forecasts, 2021 – 2033 (USD Million)
12.8.6. Oman
12.8.6.1. Key Country Dynamics
12.8.6.2. Competitive Scenario
12.8.6.3. Regulatory Framework
12.8.6.4. Oman Market Estimates and Forecasts, 2021 – 2033 (USD Million)
12.8.7. Qatar
12.8.7.1. Key Country Dynamics
12.8.7.2. Competitive Scenario
12.8.7.3. Regulatory Framework
12.8.7.4. Qatar Market Estimates and Forecasts, 2021 – 2033 (USD Million)
Chapter 13. Competitive Landscape
13.1. Market Participant Categorization
13.2. Company Market Share Analysis, 2025
13.3. Company Profiles
13.3.1. AbbVie Contract Manufacturing
13.3.1.1. Company Overview
13.3.1.2. Financial Performance
13.3.1.3. Service Benchmarking
13.3.1.4. Strategic Initiatives
13.3.2. Almac Group
13.3.2.1. Company Overview
13.3.2.2. Financial Performance
13.3.2.3. Service Benchmarking
13.3.2.4. Strategic Initiatives
13.3.3. Boehringer Ingelheim BioXcellence
13.3.3.1. Company Overview
13.3.3.2. Financial Performance
13.3.3.3. Service Benchmarking
13.3.3.4. Strategic Initiatives
13.3.4. Catalent
13.3.4.1. Company Overview
13.3.4.2. Financial Performance
13.3.4.3. Service Benchmarking
13.3.4.4. Strategic Initiatives
13.3.5. Dr. Reddy’s Laboratories
13.3.5.1. Company Overview
13.3.5.2. Financial Performance
13.3.5.3. Service Benchmarking
13.3.5.4. Strategic Initiatives
13.3.6. Fareva
13.3.6.1. Company Overview
13.3.6.2. Financial Performance
13.3.6.3. Service Benchmarking
13.3.6.4. Strategic Initiatives
13.3.7. Fujifilm Diosynth Biotechnologies
13.3.7.1. Company Overview
13.3.7.2. Financial Performance
13.3.7.3. Service Benchmarking
13.3.7.4. Strategic Initiatives
13.3.8. Jubilant HollisterStier
13.3.8.1. Company Overview
13.3.8.2. Financial Performance
13.3.8.3. Service Benchmarking
13.3.8.4. Strategic Initiatives
13.3.9. Lonza Group
13.3.9.1. Company Overview
13.3.9.2. Financial Performance
13.3.9.3. Service Benchmarking
13.3.9.4. Strategic Initiatives
13.3.10. Patheon (Thermo Fisher Scientific)
13.3.10.1. Company Overview
13.3.10.2. Financial Performance
13.3.10.3. Service Benchmarking
13.3.10.4. Strategic Initiatives
13.3.11. Pfizer CentreOne
13.3.11.1. Company Overview
13.3.11.2. Financial Performance
13.3.11.3. Service Benchmarking
13.3.11.4. Strategic Initiatives
13.3.12. Prakruti Life Science
13.3.12.1. Company Overview
13.3.12.2. Financial Performance
13.3.12.3. Service Benchmarking
13.3.12.4. Strategic Initiatives
13.3.13. Recipharm
13.3.13.1. Company Overview
13.3.13.2. Financial Performance
13.3.13.3. Service Benchmarking
13.3.13.4. Strategic Initiatives
13.3.14. Samsung Biologics
13.3.14.1. Company Overview
13.3.14.2. Financial Performance
13.3.14.3. Service Benchmarking
13.3.14.4. Strategic Initiatives
13.3.15. Siegfried Holding AG
13.3.15.1. Company Overview
13.3.15.2. Financial Performance
13.3.15.3. Service Benchmarking
13.3.15.4. Strategic Initiatives
13.3.16. Vetter Pharma
13.3.16.1. Company Overview
13.3.16.2. Financial Performance
13.3.16.3. Service Benchmarking
13.3.16.4. Strategic Initiatives
13.3.17. WuXi AppTec
13.3.17.1. Company Overview
13.3.17.2. Financial Performance
13.3.17.3. Service Benchmarking
13.3.17.4. Strategic Initiatives
Chapter 9 Key Recommendations

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Pharmaceutical Contract Manufacturing Market, by Service, 2021 – 2033 (USD Million)
Table 4 Global Pharmaceutical Contract Manufacturing Market, by Product, 2021 – 2033 (USD Million)
Table 5 Global Pharmaceutical Contract Manufacturing Market, by Drug, 2021 – 2033 (USD Million)
Table 6 Global Pharmaceutical Contract Manufacturing Market, by Scale of Operation, 2021 – 2033 (USD Million)
Table 7 Global Pharmaceutical Contract Manufacturing Market, by Workflow, 2021 – 2033 (USD Million)
Table 8 Global Pharmaceutical Contract Manufacturing Market, by Application, 2021 – 2033 (USD Million)
Table 9 Global Pharmaceutical Contract Manufacturing Market, by End Use, 2021 – 2033 (USD Million)
Table 10 Global Pharmaceutical Contract Manufacturing Market, by Company Size, 2021 – 2033 (USD Million)
Table 11 North America Pharmaceutical Contract Manufacturing Market, by Country, 2021 – 2033 (USD Million)
Table 12 North America Pharmaceutical Contract Manufacturing Market, by Service, 2021 – 2033 (USD Million)
Table 13 North America Pharmaceutical Contract Manufacturing Market, by Product, 2021 – 2033 (USD Million)
Table 14 North America Pharmaceutical Contract Manufacturing Market, by Drug, 2021 – 2033 (USD Million)
Table 15 North America Pharmaceutical Contract Manufacturing Market, by Scale of Operation, 2021 – 2033 (USD Million)
Table 16 North America Pharmaceutical Contract Manufacturing Market, by Workflow, 2021 – 2033 (USD Million)
Table 17 North America Pharmaceutical Contract Manufacturing Market, by Application, 2021 – 2033 (USD Million)
Table 18 North America Pharmaceutical Contract Manufacturing Market, by End Use, 2021 – 2033 (USD Million)
Table 19 North America Pharmaceutical Contract Manufacturing Market, by Company Size, 2021 – 2033 (USD Million)
Table 20 U.S. Pharmaceutical Contract Manufacturing Market, by Service, 2021 – 2033 (USD Million)
Table 21 U.S. Pharmaceutical Contract Manufacturing Market, by Product, 2021 – 2033 (USD Million)
Table 22 U.S. Pharmaceutical Contract Manufacturing Market, by Drug, 2021 – 2033 (USD Million)
Table 23 U.S. Pharmaceutical Contract Manufacturing Market, by Scale of Operation, 2021 – 2033 (USD Million)
Table 24 U.S. Pharmaceutical Contract Manufacturing Market, by Workflow, 2021 – 2033 (USD Million)
Table 25 U.S. Pharmaceutical Contract Manufacturing Market, by Application, 2021 – 2033 (USD Million)
Table 26 U.S. Pharmaceutical Contract Manufacturing Market, by End Use, 2021 – 2033 (USD Million)
Table 27 U.S. Pharmaceutical Contract Manufacturing Market, by Company Size, 2021 – 2033 (USD Million)
Table 28 Canada Pharmaceutical Contract Manufacturing Market, by Service, 2021 – 2033 (USD Million)
Table 29 Canada Pharmaceutical Contract Manufacturing Market, by Product, 2021 – 2033 (USD Million)
Table 30 Canada Pharmaceutical Contract Manufacturing Market, by Drug, 2021 – 2033 (USD Million)
Table 31 Canada Pharmaceutical Contract Manufacturing Market, by Scale of Operation, 2021 – 2033 (USD Million)
Table 32 Canada Pharmaceutical Contract Manufacturing Market, by Workflow, 2021 – 2033 (USD Million)
Table 33 Canada Pharmaceutical Contract Manufacturing Market, by Application, 2021 – 2033 (USD Million)
Table 34 Canada Pharmaceutical Contract Manufacturing Market, by End Use, 2021 – 2033 (USD Million)
Table 35 Canada Pharmaceutical Contract Manufacturing Market, by Company Size, 2021 – 2033 (USD Million)
Table 36 Mexico Pharmaceutical Contract Manufacturing Market, by Service, 2021 – 2033 (USD Million)
Table 37 Mexico Pharmaceutical Contract Manufacturing Market, by Product, 2021 – 2033 (USD Million)
Table 38 Mexico Pharmaceutical Contract Manufacturing Market, by Drug, 2021 – 2033 (USD Million)
Table 39 Mexico Pharmaceutical Contract Manufacturing Market, by Scale of Operation, 2021 – 2033 (USD Million)
Table 40 Mexico Pharmaceutical Contract Manufacturing Market, by Workflow, 2021 – 2033 (USD Million)
Table 41 Mexico Pharmaceutical Contract Manufacturing Market, by Application, 2021 – 2033 (USD Million)
Table 42 Mexico Pharmaceutical Contract Manufacturing Market, by End Use, 2021 – 2033 (USD Million)
Table 43 Mexico Pharmaceutical Contract Manufacturing Market, by Company Size, 2021 – 2033 (USD Million)
Table 44 Europe Pharmaceutical Contract Manufacturing, by Country, 2021 – 2033 (USD Million)
Table 45 Europe Pharmaceutical Contract Manufacturing Market, by Service, 2021 – 2033 (USD Million)
Table 46 Europe Pharmaceutical Contract Manufacturing Market, by Product, 2021 – 2033 (USD Million)
Table 47 Europe Pharmaceutical Contract Manufacturing Market, by Drug, 2021 – 2033 (USD Million)
Table 48 Europe Pharmaceutical Contract Manufacturing Market, by Scale of Operation, 2021 – 2033 (USD Million)
Table 49 Europe Pharmaceutical Contract Manufacturing Market, by Workflow, 2021 – 2033 (USD Million)
Table 50 Europe Pharmaceutical Contract Manufacturing Market, by Application, 2021 – 2033 (USD Million)
Table 51 Europe Pharmaceutical Contract Manufacturing Market, by End Use, 2021 – 2033 (USD Million)
Table 52 Europe Pharmaceutical Contract Manufacturing Market, by Company Size, 2021 – 2033 (USD Million)
Table 53 UK Pharmaceutical Contract Manufacturing Market, by Service, 2021 – 2033 (USD Million)
Table 54 UK Pharmaceutical Contract Manufacturing Market, by Product, 2021 – 2033 (USD Million)
Table 55 UK Pharmaceutical Contract Manufacturing Market, by Drug, 2021 – 2033 (USD Million)
Table 56 UK Pharmaceutical Contract Manufacturing Market, by Scale of Operation, 2021 – 2033 (USD Million)
Table 57 UK Pharmaceutical Contract Manufacturing Market, by Workflow, 2021 – 2033 (USD Million)
Table 58 UK Pharmaceutical Contract Manufacturing Market, by Application, 2021 – 2033 (USD Million)
Table 59 UK Pharmaceutical Contract Manufacturing Market, by End Use, 2021 – 2033 (USD Million)
Table 60 UK Pharmaceutical Contract Manufacturing Market, by Company Size, 2021 – 2033 (USD Million)
Table 61 Germany Pharmaceutical Contract Manufacturing Market, by Service, 2021 – 2033 (USD Million)
Table 62 Germany Pharmaceutical Contract Manufacturing Market, by Product, 2021 – 2033 (USD Million)
Table 63 Germany Pharmaceutical Contract Manufacturing Market, by Drug, 2021 – 2033 (USD Million)
Table 64 Germany Pharmaceutical Contract Manufacturing Market, by Scale of Operation, 2021 – 2033 (USD Million)
Table 65 Germany Pharmaceutical Contract Manufacturing Market, by Workflow, 2021 – 2033 (USD Million)
Table 66 Germany Pharmaceutical Contract Manufacturing Market, by Application, 2021 – 2033 (USD Million)
Table 67 Germany Pharmaceutical Contract Manufacturing Market, by End Use, 2021 – 2033 (USD Million)
Table 68 Germany Pharmaceutical Contract Manufacturing Market, by Company Size, 2021 – 2033 (USD Million)
Table 69 France Pharmaceutical Contract Manufacturing Market, by Service, 2021 – 2033 (USD Million)
Table 70 France Pharmaceutical Contract Manufacturing Market, by Product, 2021 – 2033 (USD Million)
Table 71 France Pharmaceutical Contract Manufacturing Market, by Drug, 2021 – 2033 (USD Million)
Table 72 France Pharmaceutical Contract Manufacturing Market, by Scale of Operation, 2021 – 2033 (USD Million)
Table 73 France Pharmaceutical Contract Manufacturing Market, by Workflow, 2021 – 2033 (USD Million)
Table 74 France Pharmaceutical Contract Manufacturing Market, by Application, 2021 – 2033 (USD Million)
Table 75 France Pharmaceutical Contract Manufacturing Market, by End Use, 2021 – 2033 (USD Million)
Table 76 France Pharmaceutical Contract Manufacturing Market, by Company Size, 2021 – 2033 (USD Million)
Table 77 Italy Pharmaceutical Contract Manufacturing Market, by Service, 2021 – 2033 (USD Million)
Table 78 Italy Pharmaceutical Contract Manufacturing Market, by Product, 2021 – 2033 (USD Million)
Table 79 Italy Pharmaceutical Contract Manufacturing Market, by Drug, 2021 – 2033 (USD Million)
Table 80 Italy Pharmaceutical Contract Manufacturing Market, by Scale of Operation, 2021 – 2033 (USD Million)
Table 81 Italy Pharmaceutical Contract Manufacturing Market, by Workflow, 2021 – 2033 (USD Million)
Table 82 Italy Pharmaceutical Contract Manufacturing Market, by Application, 2021 – 2033 (USD Million)
Table 83 Italy Pharmaceutical Contract Manufacturing Market, by End Use, 2021 – 2033 (USD Million)
Table 84 Italy Pharmaceutical Contract Manufacturing Market, by Company Size, 2021 – 2033 (USD Million)
Table 85 Spain Pharmaceutical Contract Manufacturing Market, by Service, 2021 – 2033 (USD Million)
Table 86 Spain Pharmaceutical Contract Manufacturing Market, by Product, 2021 – 2033 (USD Million)
Table 87 Spain Pharmaceutical Contract Manufacturing Market, by Drug, 2021 – 2033 (USD Million)
Table 88 Spain Pharmaceutical Contract Manufacturing Market, by Scale of Operation, 2021 – 2033 (USD Million)
Table 89 Spain Pharmaceutical Contract Manufacturing Market, by Workflow, 2021 – 2033 (USD Million)
Table 90 Spain Pharmaceutical Contract Manufacturing Market, by Application, 2021 – 2033 (USD Million)
Table 91 Spain Pharmaceutical Contract Manufacturing Market, by End Use, 2021 – 2033 (USD Million)
Table 92 Spain Pharmaceutical Contract Manufacturing Market, by Company Size, 2021 – 2033 (USD Million)
Table 93 Denmark Pharmaceutical Contract Manufacturing Market, by Service, 2021 – 2033 (USD Million)
Table 94 Denmark Pharmaceutical Contract Manufacturing Market, by Product, 2021 – 2033 (USD Million)
Table 95 Denmark Pharmaceutical Contract Manufacturing Market, by Drug, 2021 – 2033 (USD Million)
Table 96 Denmark Pharmaceutical Contract Manufacturing Market, by Scale of Operation, 2021 – 2033 (USD Million)
Table 97 Denmark Pharmaceutical Contract Manufacturing Market, by Workflow, 2021 – 2033 (USD Million)
Table 98 Denmark Pharmaceutical Contract Manufacturing Market, by Application, 2021 – 2033 (USD Million)
Table 99 Denmark Pharmaceutical Contract Manufacturing Market, by End Use, 2021 – 2033 (USD Million)
Table 100 Denmark Pharmaceutical Contract Manufacturing Market, by Company Size, 2021 – 2033 (USD Million)
Table 101 Sweden Pharmaceutical Contract Manufacturing Market, by Service, 2021 – 2033 (USD Million)
Table 102 Sweden Pharmaceutical Contract Manufacturing Market, by Product, 2021 – 2033 (USD Million)
Table 103 Sweden Pharmaceutical Contract Manufacturing Market, by Drug, 2021 – 2033 (USD Million)
Table 104 Sweden Pharmaceutical Contract Manufacturing Market, by Scale of Operation, 2021 – 2033 (USD Million)
Table 105 Sweden Pharmaceutical Contract Manufacturing Market, by Workflow, 2021 – 2033 (USD Million)
Table 106 Sweden Pharmaceutical Contract Manufacturing Market, by Application, 2021 – 2033 (USD Million)
Table 107 Sweden Pharmaceutical Contract Manufacturing Market, by End Use, 2021 – 2033 (USD Million)
Table 108 Sweden Pharmaceutical Contract Manufacturing Market, by Company Size, 2021 – 2033 (USD Million)
Table 109 Norway Pharmaceutical Contract Manufacturing Market, by Service, 2021 – 2033 (USD Million)
Table 110 Norway Pharmaceutical Contract Manufacturing Market, by Product, 2021 – 2033 (USD Million)
Table 111 Norway Pharmaceutical Contract Manufacturing Market, by Drug, 2021 – 2033 (USD Million)
Table 112 Norway Pharmaceutical Contract Manufacturing Market, by Scale of Operation, 2021 – 2033 (USD Million)
Table 113 Norway Pharmaceutical Contract Manufacturing Market, by Workflow, 2021 – 2033 (USD Million)
Table 114 Norway Pharmaceutical Contract Manufacturing Market, by Application, 2021 – 2033 (USD Million)
Table 115 Norway Pharmaceutical Contract Manufacturing Market, by End Use, 2021 – 2033 (USD Million)
Table 116 Norway Pharmaceutical Contract Manufacturing Market, by Company Size, 2021 – 2033 (USD Million)
Table 117 Asia Pacific Pharmaceutical Contract Manufacturing, by Country, 2021 – 2033 (USD Million)
Table 118 Asia Pacific Pharmaceutical Contract Manufacturing Market, by Service, 2021 – 2033 (USD Million)
Table 119 Asia Pacific Pharmaceutical Contract Manufacturing Market, by Product, 2021 – 2033 (USD Million)
Table 120 Asia Pacific Pharmaceutical Contract Manufacturing Market, by Drug, 2021 – 2033 (USD Million)
Table 121 Asia Pacific Pharmaceutical Contract Manufacturing Market, by Scale of Operation, 2021 – 2033 (USD Million)
Table 122 Asia Pacific Pharmaceutical Contract Manufacturing Market, by Workflow, 2021 – 2033 (USD Million)
Table 123 Asia Pacific Pharmaceutical Contract Manufacturing Market, by Application, 2021 – 2033 (USD Million)
Table 124 Asia Pacific Pharmaceutical Contract Manufacturing Market, by End Use, 2021 – 2033 (USD Million)
Table 125 Asia Pacific Pharmaceutical Contract Manufacturing Market, by Company Size, 2021 – 2033 (USD Million)
Table 126 Japan Pharmaceutical Contract Manufacturing Market, by Service, 2021 – 2033 (USD Million)
Table 127 Japan Pharmaceutical Contract Manufacturing Market, by Product, 2021 – 2033 (USD Million)
Table 128 Japan Pharmaceutical Contract Manufacturing Market, by Drug, 2021 – 2033 (USD Million)
Table 129 Japan Pharmaceutical Contract Manufacturing Market, by Scale of Operation, 2021 – 2033 (USD Million)
Table 130 Japan Pharmaceutical Contract Manufacturing Market, by Workflow, 2021 – 2033 (USD Million)
Table 131 Japan Pharmaceutical Contract Manufacturing Market, by Application, 2021 – 2033 (USD Million)
Table 132 Japan Pharmaceutical Contract Manufacturing Market, by End Use, 2021 – 2033 (USD Million)
Table 133 Japan Pharmaceutical Contract Manufacturing Market, by Company Size, 2021 – 2033 (USD Million)
Table 134 China Pharmaceutical Contract Manufacturing Market, by Service, 2021 – 2033 (USD Million)
Table 135 China Pharmaceutical Contract Manufacturing Market, by Product, 2021 – 2033 (USD Million)
Table 136 China Pharmaceutical Contract Manufacturing Market, by Drug, 2021 – 2033 (USD Million)
Table 137 China Pharmaceutical Contract Manufacturing Market, by Scale of Operation, 2021 – 2033 (USD Million)
Table 138 China Pharmaceutical Contract Manufacturing Market, by Workflow, 2021 – 2033 (USD Million)
Table 139 China Pharmaceutical Contract Manufacturing Market, by Application, 2021 – 2033 (USD Million)
Table 140 China Pharmaceutical Contract Manufacturing Market, by End Use, 2021 – 2033 (USD Million)
Table 141 China Pharmaceutical Contract Manufacturing Market, by Company Size, 2021 – 2033 (USD Million)
Table 142 India Pharmaceutical Contract Manufacturing Market, by Service, 2021 – 2033 (USD Million)
Table 143 India Pharmaceutical Contract Manufacturing Market, by Product, 2021 – 2033 (USD Million)
Table 144 India Pharmaceutical Contract Manufacturing Market, by Drug, 2021 – 2033 (USD Million)
Table 145 India Pharmaceutical Contract Manufacturing Market, by Scale of Operation, 2021 – 2033 (USD Million)
Table 146 India Pharmaceutical Contract Manufacturing Market, by Workflow, 2021 – 2033 (USD Million)
Table 147 India Pharmaceutical Contract Manufacturing Market, by Application, 2021 – 2033 (USD Million)
Table 148 India Pharmaceutical Contract Manufacturing Market, by End Use, 2021 – 2033 (USD Million)
Table 149 India Pharmaceutical Contract Manufacturing Market, by Company Size, 2021 – 2033 (USD Million)
Table 150 Thailand Pharmaceutical Contract Manufacturing Market, by Service, 2021 – 2033 (USD Million)
Table 151 Thailand Pharmaceutical Contract Manufacturing Market, by Product, 2021 – 2033 (USD Million)
Table 152 Thailand Pharmaceutical Contract Manufacturing Market, by Drug, 2021 – 2033 (USD Million)
Table 153 Thailand Pharmaceutical Contract Manufacturing Market, by Scale of Operation, 2021 – 2033 (USD Million)
Table 154 Thailand Pharmaceutical Contract Manufacturing Market, by Workflow, 2021 – 2033 (USD Million)
Table 155 Thailand Pharmaceutical Contract Manufacturing Market, by Application, 2021 – 2033 (USD Million)
Table 156 Thailand Pharmaceutical Contract Manufacturing Market, by End Use, 2021 – 2033 (USD Million)
Table 157 Thailand Pharmaceutical Contract Manufacturing Market, by Company Size, 2021 – 2033 (USD Million)
Table 158 South Korea Pharmaceutical Contract Manufacturing Market, by Service, 2021 – 2033 (USD Million)
Table 159 South Korea Pharmaceutical Contract Manufacturing Market, by Product, 2021 – 2033 (USD Million)
Table 160 South Korea Pharmaceutical Contract Manufacturing Market, by Drug, 2021 – 2033 (USD Million)
Table 161 South Korea Pharmaceutical Contract Manufacturing Market, by Scale of Operation, 2021 – 2033 (USD Million)
Table 162 South Korea Pharmaceutical Contract Manufacturing Market, by Workflow, 2021 – 2033 (USD Million)
Table 163 South Korea Pharmaceutical Contract Manufacturing Market, by Application, 2021 – 2033 (USD Million)
Table 164 South Korea Pharmaceutical Contract Manufacturing Market, by End Use, 2021 – 2033 (USD Million)
Table 165 South Korea Pharmaceutical Contract Manufacturing Market, by Company Size, 2021 – 2033 (USD Million)
Table 166 Australia Pharmaceutical Contract Manufacturing Market, by Service, 2021 – 2033 (USD Million)
Table 167 Australia Pharmaceutical Contract Manufacturing Market, by Product, 2021 – 2033 (USD Million)
Table 168 Australia Pharmaceutical Contract Manufacturing Market, by Drug, 2021 – 2033 (USD Million)
Table 169 Australia Pharmaceutical Contract Manufacturing Market, by Scale of Operation, 2021 – 2033 (USD Million)
Table 170 Australia Pharmaceutical Contract Manufacturing Market, by Workflow, 2021 – 2033 (USD Million)
Table 171 Australia Pharmaceutical Contract Manufacturing Market, by Application, 2021 – 2033 (USD Million)
Table 172 Australia Pharmaceutical Contract Manufacturing Market, by End Use, 2021 – 2033 (USD Million)
Table 173 Australia Pharmaceutical Contract Manufacturing Market, by Company Size, 2021 – 2033 (USD Million)
Table 174 Latin America Pharmaceutical Contract Manufacturing, by Country, 2021 – 2033 (USD Million)
Table 175 Latin America Pharmaceutical Contract Manufacturing Market, by Service, 2021 – 2033 (USD Million)
Table 176 Latin America Pharmaceutical Contract Manufacturing Market, by Product, 2021 – 2033 (USD Million)
Table 177 Latin America Pharmaceutical Contract Manufacturing Market, by Drug, 2021 – 2033 (USD Million)
Table 178 Latin America Pharmaceutical Contract Manufacturing Market, by Scale of Operation, 2021 – 2033 (USD Million)
Table 179 Latin America Pharmaceutical Contract Manufacturing Market, by Workflow, 2021 – 2033 (USD Million)
Table 180 Latin America Pharmaceutical Contract Manufacturing Market, by Application, 2021 – 2033 (USD Million)
Table 181 Latin America Pharmaceutical Contract Manufacturing Market, by End Use, 2021 – 2033 (USD Million)
Table 182 Latin America Pharmaceutical Contract Manufacturing Market, by Company Size, 2021 – 2033 (USD Million)
Table 183 Brazil Pharmaceutical Contract Manufacturing Market, by Service, 2021 – 2033 (USD Million)
Table 184 Brazil Pharmaceutical Contract Manufacturing Market, by Product, 2021 – 2033 (USD Million)
Table 185 Brazil Pharmaceutical Contract Manufacturing Market, by Drug, 2021 – 2033 (USD Million)
Table 186 Brazil Pharmaceutical Contract Manufacturing Market, by Scale of Operation, 2021 – 2033 (USD Million)
Table 187 Brazil Pharmaceutical Contract Manufacturing Market, by Workflow, 2021 – 2033 (USD Million)
Table 188 Brazil Pharmaceutical Contract Manufacturing Market, by Application, 2021 – 2033 (USD Million)
Table 189 Brazil Pharmaceutical Contract Manufacturing Market, by End Use, 2021 – 2033 (USD Million)
Table 190 Brazil Pharmaceutical Contract Manufacturing Market, by Company Size, 2021 – 2033 (USD Million)
Table 191 Argentina Pharmaceutical Contract Manufacturing Market, by Service, 2021 – 2033 (USD Million)
Table 192 Argentina Pharmaceutical Contract Manufacturing Market, by Product, 2021 – 2033 (USD Million)
Table 193 Argentina Pharmaceutical Contract Manufacturing Market, by Drug, 2021 – 2033 (USD Million)
Table 194 Argentina Pharmaceutical Contract Manufacturing Market, by Scale of Operation, 2021 – 2033 (USD Million)
Table 195 Argentina Pharmaceutical Contract Manufacturing Market, by Workflow, 2021 – 2033 (USD Million)
Table 196 Argentina Pharmaceutical Contract Manufacturing Market, by Application, 2021 – 2033 (USD Million)
Table 197 Argentina Pharmaceutical Contract Manufacturing Market, by End Use, 2021 – 2033 (USD Million)
Table 198 Argentina Pharmaceutical Contract Manufacturing Market, by Company Size, 2021 – 2033 (USD Million)
Table 199 Middle East & Africa Pharmaceutical Contract Manufacturing, by Country, 2021 – 2033 (USD Million)
Table 200 Middle East & Africa Pharmaceutical Contract Manufacturing Market, by Service, 2021 – 2033 (USD Million)
Table 201 Middle East & Africa Pharmaceutical Contract Manufacturing Market, by Product, 2021 – 2033 (USD Million)
Table 202 Middle East & Africa Pharmaceutical Contract Manufacturing Market, by Drug, 2021 – 2033 (USD Million)
Table 203 Middle East & Africa Pharmaceutical Contract Manufacturing Market, by Scale of Operation, 2021 – 2033 (USD Million)
Table 204 Middle East & Africa Pharmaceutical Contract Manufacturing Market, by Workflow, 2021 – 2033 (USD Million)
Table 205 Middle East & Africa Pharmaceutical Contract Manufacturing Market, by Application, 2021 – 2033 (USD Million)
Table 206 Middle East & Africa Pharmaceutical Contract Manufacturing Market, by End Use, 2021 – 2033 (USD Million)
Table 207 Middle East & Africa Pharmaceutical Contract Manufacturing Market, by Company Size, 2021 – 2033 (USD Million)
Table 208 South Africa Pharmaceutical Contract Manufacturing Market, by Service, 2021 – 2033 (USD Million)
Table 209 South Africa Pharmaceutical Contract Manufacturing Market, by Product, 2021 – 2033 (USD Million)
Table 210 South Africa Pharmaceutical Contract Manufacturing Market, by Drug, 2021 – 2033 (USD Million)
Table 211 South Africa Pharmaceutical Contract Manufacturing Market, by Scale of Operation, 2021 – 2033 (USD Million)
Table 212 South Africa Pharmaceutical Contract Manufacturing Market, by Workflow, 2021 – 2033 (USD Million)
Table 213 South Africa Pharmaceutical Contract Manufacturing Market, by Application, 2021 – 2033 (USD Million)
Table 214 South Africa Pharmaceutical Contract Manufacturing Market, by End Use, 2021 – 2033 (USD Million)
Table 215 South Africa Pharmaceutical Contract Manufacturing Market, by Company Size, 2021 – 2033 (USD Million)
Table 216 Saudi Arabia Pharmaceutical Contract Manufacturing Market, by Service, 2021 – 2033 (USD Million)
Table 217 Saudi Arabia Pharmaceutical Contract Manufacturing Market, by Product, 2021 – 2033 (USD Million)
Table 218 Saudi Arabia Pharmaceutical Contract Manufacturing Market, by Drug, 2021 – 2033 (USD Million)
Table 219 Saudi Arabia Pharmaceutical Contract Manufacturing Market, by Scale of Operation, 2021 – 2033 (USD Million)
Table 220 Saudi Arabia Pharmaceutical Contract Manufacturing Market, by Workflow, 2021 – 2033 (USD Million)
Table 221 Saudi Arabia Pharmaceutical Contract Manufacturing Market, by Application, 2021 – 2033 (USD Million)
Table 222 Saudi Arabia Pharmaceutical Contract Manufacturing Market, by End Use, 2021 – 2033 (USD Million)
Table 223 Saudi Arabia Pharmaceutical Contract Manufacturing Market, by Company Size, 2021 – 2033 (USD Million)
Table 224 UAE Pharmaceutical Contract Manufacturing Market, by Service, 2021 – 2033 (USD Million)
Table 225 UAE Pharmaceutical Contract Manufacturing Market, by Product, 2021 – 2033 (USD Million)
Table 226 UAE Pharmaceutical Contract Manufacturing Market, by Drug, 2021 – 2033 (USD Million)
Table 227 UAE Pharmaceutical Contract Manufacturing Market, by Scale of Operation, 2021 – 2033 (USD Million)
Table 228 UAE Pharmaceutical Contract Manufacturing Market, by Workflow, 2021 – 2033 (USD Million)
Table 229 UAE Pharmaceutical Contract Manufacturing Market, by Application, 2021 – 2033 (USD Million)
Table 230 UAE Pharmaceutical Contract Manufacturing Market, by End Use, 2021 – 2033 (USD Million)
Table 231 UAE Pharmaceutical Contract Manufacturing Market, by Company Size, 2021 – 2033 (USD Million)
Table 232 Kuwait Pharmaceutical Contract Manufacturing Market, by Service, 2021 – 2033 (USD Million)
Table 233 Kuwait Pharmaceutical Contract Manufacturing Market, by Product, 2021 – 2033 (USD Million)
Table 234 Kuwait Pharmaceutical Contract Manufacturing Market, by Drug, 2021 – 2033 (USD Million)
Table 235 Kuwait Pharmaceutical Contract Manufacturing Market, by Scale of Operation, 2021 – 2033 (USD Million)
Table 236 Kuwait Pharmaceutical Contract Manufacturing Market, by Workflow, 2021 – 2033 (USD Million)
Table 237 Kuwait Pharmaceutical Contract Manufacturing Market, by Application, 2021 – 2033 (USD Million)
Table 238 Kuwait Pharmaceutical Contract Manufacturing Market, by End Use, 2021 – 2033 (USD Million)
Table 239 Kuwait Pharmaceutical Contract Manufacturing Market, by Company Size, 2021 – 2033 ((USD Million)
Table 240 Financial performance

List of Figures

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Market formulation & validation
Fig. 6 Commodity flow analysis
Fig. 7 Value-chain-based sizing & forecasting
Fig. 8 QFD model sizing & forecasting
Fig. 9 Bottom-up approach
Fig. 10 Market snapshot
Fig. 11 Segment snapshot 1
Fig. 12 Segment snapshot 2
Fig. 13 Competitive landscape snapshot
Fig. 14 Parent market outlook, 2024 (USD Billion)
Fig. 15 Ancillary market outlook, 2024 (USD Billion)
Fig. 16 Pharmaceutical Contract Manufacturing Market dynamics
Fig. 17 Porter’s five forces analysis
Fig. 18 PESTEL analysis
Fig. 19 Pharmaceutical Contract Manufacturing Market: Service outlook and key takeaways
Fig. 20 Pharmaceutical Contract Manufacturing Market: Service movement analysis
Fig. 21 API manufacturing market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 22 Finished drug product manufacturing market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 23 Oral solids market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 24 Liquids market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 25 Topical market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 26 Others market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 27 Packaging services market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 28 Pharmaceutical Contract Manufacturing Market: Product outlook and key takeaways
Fig. 29 Pharmaceutical Contract Manufacturing Market: Product movement analysis
Fig. 30 Small molecule market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 31 Biologics market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 32 Monoclonal antibodies market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 33 Vaccines market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 34 Recombinant proteins market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 35 Others market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 36 Pharmaceutical Contract Manufacturing Market: Drug outlook and key takeaways
Fig. 37 Pharmaceutical Contract Manufacturing Market: Drug movement analysis
Fig. 38 Generics market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 39 Branded market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 40 Pharmaceutical Contract Manufacturing Market: Scale of operation outlook and key takeaways
Fig. 41 Pharmaceutical Contract Manufacturing Market: Scale of operation movement analysis
Fig. 42 Batch market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 43 Continuous market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 44 Pharmaceutical Contract Manufacturing Market: Workflow outlook and key takeaways
Fig. 45 Pharmaceutical Contract Manufacturing Market: Workflow movement analysis
Fig. 46 Clinical market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 47 Commercial market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 48 Pharmaceutical Contract Manufacturing Market: Application outlook and key takeaways
Fig. 49 Pharmaceutical Contract Manufacturing Market: Application movement analysis
Fig. 50 Oncology market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 51 Infectious diseases market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 52 Neurological disorders market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 53 Cardiovascular disease market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 54 Metabolic disorders market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 55 Autoimmune diseases market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 56 Respiratory diseases market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 57 Ophthalmology market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 58 Gastrointestinal disorders market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 59 Hormonal disorders market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 60 Hematological disorders market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 61 Others market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 62 Pharmaceutical Contract Manufacturing Market: End Use outlook and key takeaways
Fig. 63 Pharmaceutical Contract Manufacturing Market: End Use movement analysis
Fig. 64 Pharmaceutical companies market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 65 Biotechnology companies market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 66 Pharmaceutical Contract Manufacturing Market: Company Size outlook and key takeaways
Fig. 67 Pharmaceutical Contract Manufacturing Market: Company Size movement analysis
Fig. 68 Small market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 69 Medium market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 70 Large market estimates and forecast, 2021 – 2033 (USD Million)
Fig. 71 Regional Marketplace: Key Takeaways
Fig. 72 North America Pharmaceutical Contract Manufacturing Market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 73 Key country dynamics
Fig. 74 U.S. Pharmaceutical Contract Manufacturing Market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 75 Key country dynamics
Fig. 76 Canada Pharmaceutical Contract Manufacturing Market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 77 Key country dynamics
Fig. 78 Mexico Pharmaceutical Contract Manufacturing Market estimates and forecasts, 2021 – 2033 (USD Million)
Fig. 79 Europe Pharmaceutical Contract Manufacturing Market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 80 Key country dynamics
Fig. 81 UK Pharmaceutical Contract Manufacturing Market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 82 Key country dynamics
Fig. 83 Germany Pharmaceutical Contract Manufacturing Market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 84 Key country dynamics
Fig. 85 France Pharmaceutical Contract Manufacturing Market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 86 Key country dynamics
Fig. 87 Italy Pharmaceutical Contract Manufacturing Market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 88 Key country dynamics
Fig. 89 Spain Pharmaceutical Contract Manufacturing Market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 90 Key country dynamics
Fig. 91 Denmark outsourcing market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 92 Key country dynamics
Fig. 93 Sweden outsourcing market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 94 Key country dynamics
Fig. 95 Norway outsourcing market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 96 Asia Pacific Pharmaceutical Contract Manufacturing Market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 97 Key country dynamics
Fig. 98 Japan Pharmaceutical Contract Manufacturing Market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 99 Key country dynamics
Fig. 100 China Pharmaceutical Contract Manufacturing Market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 101 Key country dynamics
Fig. 102 India Pharmaceutical Contract Manufacturing Market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 103 Key country dynamics
Fig. 104 Thailand Pharmaceutical Contract Manufacturing Market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 105 Key country dynamics
Fig. 106 South Korea Pharmaceutical Contract Manufacturing Market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 107 Key country dynamics
Fig. 108 Australia Pharmaceutical Contract Manufacturing Market estimates and forecasts, 2018 – 2030 (USD Million)
Fig. 109 Latin America Pharmaceutical Contract Manufacturing Market estimates and forecasts, 2021 – 2033 (USD Million)
Fig. 110 Key country dynamics
Fig. 111 Brazil Pharmaceutical Contract Manufacturing Market estimates and forecasts, 2021 – 2033 (USD Million)
Fig. 112 Key country dynamics
Fig. 113 Argentina Pharmaceutical Contract Manufacturing Market estimates and forecasts, 2021 – 2033 (USD Million)
Fig. 114 MEA Pharmaceutical Contract Manufacturing Market estimates and forecasts, 2021 – 2033 (USD Million)
Fig. 115 Key country dynamics
Fig. 116 South Africa Pharmaceutical Contract Manufacturing Market estimates and forecasts, 2021 – 2033 (USD Million)
Fig. 117 Fig. Key country dynamics
Fig. 118 Saudi Arabia Pharmaceutical Contract Manufacturing Market estimates and forecasts, 2021 – 2033 (USD Million)
Fig. 119 Key country dynamics
Fig. 120 UAE Pharmaceutical Contract Manufacturing Market estimates and forecasts, 2021 – 2033 (USD Million)
Fig. 121 Key country dynamics
Fig. 122 Kuwait Pharmaceutical Contract Manufacturing Market estimates and forecasts, 2021 – 2033 (USD Million)
Fig. 123 Key company categorization
Fig. 124 Service heat map analysis
Fig. 125 Strategic framework

---

---